Journal List > Korean J Gastroenterol > v.78(3) > 1147561

TOOLS
KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement
CORRECTION

Korean J Gastroenterol 2021;78(3):202-203.

Published online: 25 September 2021

DOI: https://doi.org/10.4166/kjg.2021.78.3.202

COVID-19 유행 시기의 성인 염증성 장질환 임상 진료지침: 전문가 합의 권고문

박용은1,*, 이유진2,*, 장지영3, 송현주4, 김덕환5, 양영주6, 김병창7, 이재곤8, 양희찬9, 최미영10, 김성은11,**, 명승재12,**

1인제대학교 의과대학 해운대백병원 소화기내과

2계명대학교 의과대학 동산의료원 소화기내과

3이화여자대학교 의과대학 이대서울병원 건진의학과

4제주대학교 의과대학 제주대학교병원 소화기내과

5CHA 의과학대학교 분당차병원 소화기센터

6한림대학교 의과대학 한림대학교 춘천성심병원 소화기내과

7국립암센터 대장암센터

8한림대학교 의과대학 한림대학교 동탄성심병원 소화기내과

9전북대학교 의과대학 전북대학교병원 소화기내과

10한국보건의료연구원 임상근거연구팀

11이화여자대학교 의과대학 이대목동병원 소화기내과

12울산대학교 의과대학 서울아산병원 소화기내과

KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement

Yong Eun Park1,*, Yoo Jin Lee2,*, Ji Young Chang3, Hyun Joo Song4, Duk Hwan Kim5, Young Joo Yang6, Byung Chang Kim7, Jae Gon Lee8, Hee Chan Yang9, Miyoung Choi10, Seong-Eun Kim11,**, Seung-Jae Myung12,**

1Division of Gastroenterology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea

2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea

3Department of Health Promotion Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Korea

4Division of Gastroenterology, Department of Internal Medicine, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, Korea

5Digestive Disease Center, CHA Bundang Hospital, CHA University, Seongnam, Korea

6Division of Gastroenterology, Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea

7Center for Colorectal Cancer, National Cancer Center, Goyang, Korea

8Division of Gastroenterology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea

9Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea

10Division of Healthcare Technology Assessment Research, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea

11Division of Gastroenterology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea

12Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Copyright © 2021. Korean Society of Gastroenterology.

(open-access):

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Korean J Gastroenterol 2021;78:105-116 https://doi.org/10.4166/kjg.2021.112
대한소화기학회지에 게재된 위 논문에서 초록을 정정합니다.
This correction is being published to correct the abstract in above article.
Before correction
The coronavirus disease 2019 (COVID-19) pandemic has reduced the ability to prevent or control chronic disease due to the concerns about safety in accessing health care. Inflammatory bowel disease (IBD) is a chronic condition requiring long- term sustained treatment, which is difficult in the current panedemic situation. The Korean Association for the Study of Intestinal Diseases (KASID) has developed an expert consensus statement on the clinical practice management of adult inflammatory bowel disease during the COVID-19 pandemic. This expert consensus statement is based on guidelines and clinical reports from several countries around the world. It provides recommendations to deal with the risk of COVID-19 and medication use in IBD patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and emphasizes the importance of right treatment approach to avoid worsening of the disease condition in IBD patients.
After correction
Many unexpected problems have resulted from the unprecedented COVID-19 pandemic. The optimal management of patients with inflammatory bowel disease (IBD) during the COVID-19 pandemic has also been a challenge. Therefore, the Korean Association for the Study of Intestinal Diseases (KASID) developed a consensus statement of experts regarding the management of IBD during the COVID-19 pandemic. This consensus statement made recommendations regarding the risk and treatment of COVID-19 in IBD patients. This statement emphasizes that IBD is not a risk factor for COVID-19, and care should be taken not to exacerbate IBD in patients in remission state by maintaining their medications, except for corticosteroids.
TOOLS
Similar articles